A new method to assess the safety of genome editing therapies

Sensitive, unbiased, high-throughput, cellular GUIDE-seq-2 genome-wide activity assay for therapeutic genome editing INDs

NIH-funded research St. Jude Children's Research Hospital · NIH-11093584

This study is working on a new test to make sure that gene editing treatments are safe and don’t accidentally cause harmful changes in your DNA, so that these therapies can be safer for patients like you.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11093584 on NIH RePORTER

What this research studies

This research focuses on developing a refined assay called GUIDE-seq-2, which aims to evaluate the safety and effectiveness of genome editing therapies. By identifying and characterizing unintended mutations that could arise during the editing process, the research seeks to ensure that these therapies do not activate harmful genes. Patients may benefit from this work as it aims to enhance the safety profile of potential gene therapies, making them safer for clinical use. The approach involves optimizing and qualifying this assay for regulatory submissions, ensuring that it meets the necessary standards for therapeutic applications.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with genetic conditions or cancers that may be treated with genome editing therapies.

Not a fit: Patients who do not have genetic disorders or cancers may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to safer genome editing therapies for patients with genetic disorders or cancers.

How similar studies have performed: Other research has shown success with similar genome editing safety assessments, indicating a promising avenue for improving therapeutic applications.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapyanticancer immunotherapycancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.